Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, et al. Management recommendations for pancreatic manifestations of Von Hippel-Lindau disease. Cancer. 2022;128(3):435–46.

Article  CAS  PubMed  Google Scholar 

Halperin R, Tirosh A. Non-interventional management of advanced pancreatic neuroendocrine neoplasms in patients with Von Hippel-Lindau Disease. Cancers (Basel). 2023;15(6).

Halperin R, Arnon L, Eden-Friedman Y, Tirosh A. Unique characteristics of patients with Von Hippel-Lindau Disease defined by various diagnostic criteria. Cancers (Basel). 2023;15(6).

van Leeuwaarde RS, Ahmad S, van Nesselrooij B, Zandee W, Giles RH et al. Von Hippel-Lindau Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, editors. GeneReviews((R)). Seattle (WA) 1993.

Geurts JL. Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2020;11(3):559–66.

Article  PubMed  PubMed Central  Google Scholar 

Launbjerg K, Bache I, Galanakis M, Bisgaard ML, Binderup MLM. Von Hippel-Lindau development in children and adolescents. Am J Med Genet A. 2017;173(9):2381–94.

Article  PubMed  Google Scholar 

Louise MBM, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG, Moller HU, et al. Von Hippel-Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022;65(8):104538.

Article  Google Scholar 

Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7 Suppl):1807–43.

Article  PubMed  Google Scholar 

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

Article  PubMed  Google Scholar 

Huguet I, Grossman AB, O’Toole D. Changes in the epidemiology of neuroendocrine tumours. Neuroendocrinology. 2017;104(2):105–11.

Article  CAS  PubMed  Google Scholar 

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

Article  PubMed  PubMed Central  Google Scholar 

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.

Article  CAS  PubMed  Google Scholar 

Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2000;6(3):249–52.

Article  CAS  PubMed  Google Scholar 

Lenders JW, Eisenhofer G, Mannelli M, Pacak K, Phaeochromocytoma. Lancet. 2005;366(9486):665–75.

Article  PubMed  Google Scholar 

Neumann HPH, Young WF Jr., Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552–65.

Article  CAS  PubMed  Google Scholar 

Sbardella E, Grossman AB. Pheochromocytoma: an approach to diagnosis. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101346.

Article  CAS  PubMed  Google Scholar 

Alrezk R, Suarez A, Tena I, Pacak K. Update of Pheochromocytoma syndromes: Genetics, biochemical evaluation, and imaging. Front Endocrinol (Lausanne). 2018;9:515.

Article  PubMed  PubMed Central  Google Scholar 

Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A, et al. Preventive medicine of Von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018;25(9):783–93.

Article  CAS  PubMed  Google Scholar 

Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, et al. Clinical, genetic and radiographic analysis of 108 patients with Von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007;142(6):814–8. discussion 8 e1-2.

Article  PubMed  Google Scholar 

Igarashi H, Ito T, Nishimori I, Tamura K, Yamasaki I, Tanaka M, et al. Pancreatic involvement in Japanese patients with Von Hippel-Lindau disease: results of a nationwide survey. J Gastroenterol. 2014;49(3):511–6.

Article  CAS  PubMed  Google Scholar 

Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS Consensus guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.

Article  CAS  PubMed  Google Scholar 

Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, et al. Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with Von Hippel-Lindau Disease. JAMA Oncol. 2018;4(1):124–6.

Article  PubMed  Google Scholar 

Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS Consensus guidelines for the standards of Care in Neuroendocrine tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105(3):212–44.

Article  CAS  PubMed  Google Scholar 

Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, et al. Assessment of tumor growth in pancreatic neuroendocrine tumors in Von Hippel Lindau syndrome. J Am Coll Surg. 2014;218(2):163–9.

Article  PubMed  Google Scholar 

Shell J, Tirosh A, Millo C, Sadowski SM, Assadipour Y, Green P, et al. The utility of (68)Gallium-DOTATATE PET/CT in the detection of Von Hippel-Lindau disease associated tumors. Eur J Radiol. 2019;112:130–5.

Article  PubMed  Google Scholar 

Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, et al. Neuroendocrine tumors of the pancreas in Von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002;225(3):751–8.

Article  PubMed  Google Scholar 

van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Koopmans KP, et al. Potential value of EUS in pancreatic surveillance of VHL patients. Eur J Endocrinol. 2016;174(5):611–20.

Article  PubMed  Google Scholar 

Sadowski SM, Weisbrod AB, Ellis R, Patel D, Alimchandani M, Quezado M, et al. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with Von hippel-lindau-associated pancreatic lesions. J Am Coll Surg. 2014;218(5):997–1003.

Article  PubMed  PubMed Central  Google Scholar 

Tsoli M, Daskalakis K, Kassi E, Kaltsas G, Tsolakis AV. A critical Appraisal of contemporary and novel biomarkers in Pheochromocytomas and Adrenocortical tumors. Biology (Basel). 2021;10(7).

Tirosh A, Papadakis GZ, Millo C, Sadowski SM, Herscovitch P, Pacak K, et al. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total (68)Ga-DOTATATE-Avid tumor volume measurements. Eur J Endocrinol. 2017;176(5):575–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, et al. Pilot trial of sunitinib therapy in patients with Von Hippel-Lindau disease. Ann Oncol. 2011;22(12):2661–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, et al. Pazopanib in patients with Von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018;19(10):1351–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for Renal Cell Carcinoma in Von Hippel-Lindau Disease. N Engl J Med. 2021;385(22):2036–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, et al. Guidelines for surveillance of patients with Von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023;129(19):2927–40.

Article  PubMed  Google Scholar 

Nolting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2022;43(2):199–239.

Article  PubMed